Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type* t7 r& x) f6 e' l0 L
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
9 L8 b* a1 R0 b* z+ Author Affiliations3 d# i$ l% Z6 {/ T! h! \
% J* q/ u% J( x' P/ r$ g' u
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 M3 u1 E5 H7 H& f. ?$ `" |2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ K+ U# v7 J- i" C [$ y. u3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" E+ X5 G" c) x) a, X4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan % P7 A! B0 B6 |% l5 e1 C6 h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan & o7 F) _$ b4 s+ }
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ' d* d* h) g& W) f7 T
7Kinki University School of Medicine, Osaka 589-8511, Japan
6 m- k9 z D' b/ g8Izumi Municipal Hospital, Osaka 594-0071, Japan
) i9 K, @$ @" @' i. Q! j9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan # w8 \1 o1 H. V/ Q* C0 B/ @
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
6 a" }8 K/ V4 z1 lAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
& D5 B# {, P, F/ P5 t" \
: w& y1 f+ a# R# i. r$ O |